142 related articles for article (PubMed ID: 25577762)
1. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
van der Leeuw J; Oemrawsingh RM; van der Graaf Y; Brugts JJ; Deckers JW; Bertrand M; Fox K; Ferrari R; Remme WJ; Simoons ML; Boersma E; Visseren FL
Int J Cardiol; 2015 Mar; 182():194-9. PubMed ID: 25577762
[TBL] [Abstract][Full Text] [Related]
2. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
[TBL] [Abstract][Full Text] [Related]
3. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
[TBL] [Abstract][Full Text] [Related]
4. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
[TBL] [Abstract][Full Text] [Related]
5. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
[TBL] [Abstract][Full Text] [Related]
6. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
8. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
9. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
Scheen AJ; Legrand V
Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
[TBL] [Abstract][Full Text] [Related]
11. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
[TBL] [Abstract][Full Text] [Related]
12. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
[TBL] [Abstract][Full Text] [Related]
13. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.
Dorresteijn JA; Boekholdt SM; van der Graaf Y; Kastelein JJ; LaRosa JC; Pedersen TR; DeMicco DA; Ridker PM; Cook NR; Visseren FL
Circulation; 2013 Jun; 127(25):2485-93. PubMed ID: 23674398
[TBL] [Abstract][Full Text] [Related]
14. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
15. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
Brugts JJ; Boersma E; Simoons ML
Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
Bots ML; Remme WJ; Lüscher TF; Fox KM; Bertrand M; Ferrari R; Simoons ML; Grobbee DE;
Cardiovasc Drugs Ther; 2007 Aug; 21(4):269-79. PubMed ID: 17657599
[TBL] [Abstract][Full Text] [Related]
18. Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
Remme WJ; Deckers JW; Fox KM; Ferrari R; Bertrand M; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):161-70. PubMed ID: 18931896
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
20. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]